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evaluated by Subjective Global Assessment (SGA). The
comorbidity of each patient was stratiﬁed by Index of Co-
Existent Disease (ICED). The MOS-Short Form 36 ques-
tionnaire was ﬁlled at home by patients to evaluate their
HRQoL. The eight multi-items scales, General Health
(GH), Role Physical (RP), Physical Function (PF), Role
Emotional (RE), Social Function (SF), Bodily Pain (BP),
Emotional Well-Being (EW-B), Energy/Fatigue (EF) were
summarized into two scores: Physical Component Score
(PCS), Mental Component Score (MCS).The scores were
expressed as median value. U-Mann Withney test was
used to compare the scores of the eight domains measured
by SF-36. QoL correlates were investigated with a series
of logistic regression analyses, where questionnaire
scores, dychotomised using the median value as cut-off,
were the depend variables. Results are thus expressed in
terms of Odds Ratio. RESULTS: The patients on CAPD
had a better, but not statistically signiﬁcant, self-percep-
tion of GH, SFand BP. The scores of the other domains
were signiﬁcantly better in CAPD than in CHD patients
(RP: 37vs37p < 0.02; PF: 75vs20p < 0.001; RE: 83vs20p
< 0.0002; EWB: 50vs45p < 0.0001; EF: 64vs52p < 0.01;
PCS: 40vs36p < 0.05; MCS: 43vs39 p < 0.05). Among
clinical correlates, female sex (OR: 3.34–95% CI:
1.12–9.03 p < 0.002), age > 58 years (OR: 3.81–95% 
CI -1.33–10.9 p < 0.01), SGA ≥ 1 (OR: 5.6–95% CI:
1.8–17.5 p < 0.001) high comorbidity (OR: 2.25–95%
CI: 1.5–13.4 p < 0.005) were signiﬁcantly associated 
to lower values of PCS. MCS was lower in patients 
with diuresis <500ml/die. CONCLUSIONS: Patients on
CAPD had a better self-perception of QoL until signiﬁ-
cant diuresis was manteined.
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OBJECTIVE: The degree of severity of the undesirable
mictional problems caused by BPH is assessed according
to the scores obtained in the acknowledged and validated
IPSS questionnaire. METHOD: In accordance with 
the WHO recommendations, the IPSS was proposed to
patients (n = 189) in the form of a self-questionnaire with
the aim of analyzing the obstruction and irritation scores
for the patients suffering from a recently diagnosed BPH
and treated with Serenoa Repens. RESULTS: The IPSS
obstruction score was respectively 6.7 (3.8) and 5.9 (3.5)
upon patient inclusion and after six months. This noted
difference is statistically signiﬁcant (p < 0.0001). The IPSS
irritation score was respectively 5.5 (2.6) and 4.5 (2.3)
upon patient inclusion and after six months. This dif-
ference is here statistically signiﬁcant with p < 0.0001.
CONCLUSION: Treatment by ﬁrst intention with
Serenoa Repens thus showed a signiﬁcant improvement
as demonstrated by both the obstruction and irritation
scores.
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OBJECTIVE: Undesirable mictional problems caused by
a BPH have been found in 20 to 25% of the male popu-
lation over 50 years old. This condition can thus be 
considered as a public health problem that offers many
aspects in terms of diagnosis, therapeutics or economics.
METHOD: Within the framework of a follow-up cohort
study, a patient population suffering from a recently diag-
nosed BPH and treated with Serenoa repens (n = 158) was
asked to ﬁll in questionnaires SF12 and SPI upon inclu-
sion and 6 months later. RESULTS: When looking at the
SF-12, the results were organized in 2 types of scores: 
psychological (MCS-12) and physical (PCS-12). The SF12
scores upon patient inclusion were: PCS-12 = 41.7 and
MCS-12 = 46.5. The SF12 scores after 6 months were:
PCS-12 = 45.4 and MCS-12 = 46.9. These results bring
out a signiﬁcant improvement in the physical dimension
of the SF-12 (p < 0.0001). The SPI score upon patient
inclusion was 12.6 and reached 10.8 after 6 months of
treatment. This improvement is statistically signiﬁcant 
(p < 0.0001). CONCLUSION: Treatment by ﬁrst inten-
tion with Serenoa repens thus showed a signiﬁcant
improvement as demonstrated by the 2 validated scales,
SF12 and SPI.
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OBJECTIVE: Undesirable mictional problems caused by
a BPH—benign prostatic hypertrophy—have been found
in 20 to 25% of the male population over 50 years old.
This condition can thus be considered as a public health
problem that offers many aspects in terms of diagnosis,
therapeutics or economics. METHOD: Using a follow-up
cohort study, we isolated two groups presenting a recently
diagnosed BPH: the ﬁrst patient population was kept
under medical supervision (n = 101) versus a second
patient population undergoing treatment with Serenoa
Repens (n = 112). RESULTS: For the patients under
medical supervision, the IPSS score was respectively 11.8
(5.7) and 10.9 (6.7) upon patient inclusion and after 6
months. This difference is not statistically signiﬁcant.
However, for the patients treated with Serenoa Repens,
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the IPSS score was respectively 14.3 (6.6) and 11.9 (5.7)
upon patient inclusion and after 6 months. The noted 
difference is statistically signiﬁcant (p < 0.0001). CON-
CLUSION: Patients suffering from a recently diagnosed
BPH and treated with Serenoa Repens thus showed a sta-
tistically signiﬁcant improvement as demonstrated by the
IPSS score.
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OBJECTIVES: The objective of this study was to use con-
joint analysis (CA) to measure patients’ valuations of the
characteristics of drugs used to treat overactive bladder
(OAB) in monetary terms. METHODS: A CA survey
using a discrete choice method was administered in inter-
views with OAB patients in three clinics in the UK
between July 1999 and April 2000. The survey consisted
of a series of pairs of hypothetical OAB drug proﬁles
described in terms of treatment attributes with varying
levels. For each pair the patients were asked to select the
drug proﬁle they preferred. The drug proﬁles included
efﬁcacy attributes (e.g. reduction in urinary incontinence)
and side-effect attributes (e.g. incidence of dry mouth). A
cost attribute was included to allow the calculation of
patients’ valuations of the different attributes in mone-
tary terms. RESULTS: One thousand ﬁve hundred 
twenty discrete choice comparisons of hypothetical OAB
drug treatments were obtained from 95 patients. Based
on these responses, a logit model was estimated that
attempted to explain the reasons why the respondents
made the choices they did. From this model, it is possi-
ble to derive estimates of the implied willingness-to-pay
(WTP) of patients for improvements in OAB drug efﬁcacy
rates and for the incidence of OAB drug-related side
effects. Improvements in efﬁcacy attributes have positive
WTP estimates (from £2.20 to £11.22 per day) and the
WTP estimates are negative for the incidence of side-effect
attributes (from -£2.79 to -£9.83 per day). CONCLU-
SIONS: This study demonstrates the capability of the CA
technique to measure valuations of varying drug proﬁles
in monetary terms. The results of this study could be used
to estimate the WTP of patients for different OAB drug
treatments.
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OBJECTIVES: Overactive Bladder (OAB) patients with
symptoms of frequency, urgency, and urge incontinence
treated with tolterodine showed signiﬁcant improvement
over placebo on 6 (4mg ER) or seven (2mg IR) of 10
King’s Health Questionnaire (KHQ) domains in a 12-
week randomized, double-blind trial (Phase A). Patients
were permitted to continue in a 12-month open-label
study (Phase B) to assess long-term effects of toltero-
dine ER. Regional differences in treatment effects on
health-related quality of life (HRQoL) were assessed.
METHODS: The KHQ was administered at baseline, end
of Phase A, and after 3 and 12 months in Phase B. An
intent-to-treat population for whom KHQ translations
were available (n = 858) was used in ANCOVA models
with baseline score, age, and gender as covariates. Region
and placebo effects were measured using a model with
treatment, region, and treatment by region as factors.
Long-term effects of tolterodine were assessed using a
split plot, repeated measures model where visits and treat-
ment were factors. RESULTS: Change from baseline to
end of Phase B analysis showed no signiﬁcant differences
in KHQ scores between patients in North America (US =
439, Canada = 67) and the rest of the world (Europe plus
Australia and New Zealand [EU+, n = 332]). Only the
Personal Relationships domain showed evidence of a
region interaction effect. Change from rollover analysis
of a subgroup of U.S. patients (n = 305) showed that
treatment effects persisted (8 domains) or improved (2
domains) after 12 months of additional treatment. These
results are generally consistent with the pooled analysis.
CONCLUSIONS: Treatment with tolterodine improves
HRQoL and improvements observed after initial treat-
ment persist in the longer term. In general, physical 
and symptom domains improved quickly and changes in
social and psychological domains became evident after
longer treatment. There does not appear to be a differ-
ence in these effects by region.
URINARY & KIDNEY DISEASES/DISORDERS—
Healthcare Policy
PRK14
PREVALENCE OF APPROPRIATE URINARY
INCONTINENCE EVALUATIONS IN TEXAS
NURSING HOME FACILITIES
Monroe DM1, Rascati KL2
1Texas Department of Human Services, Austin,TX, USA; 2The
University of Texas, Austin,TX, USA
